Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models

被引:10
|
作者
Yang, Mei [1 ]
Guan, Tian [2 ]
Chen, Chun-Fa [3 ]
He, Li-Fang [3 ]
Wu, Hao-Ming [3 ]
Zhang, Ren-Dong [3 ]
Li, Yun [2 ]
Lin, Yan-Chun [2 ]
Zeng, Haoyu [2 ,6 ]
Wu, Jun-Dong [3 ,4 ,5 ]
机构
[1] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Canc Ctr, Dept Breast Canc, Shantou, Guangdong, Peoples R China
[2] Guangdong Procapzoom Biosci Inc, Guangzhou, Guangdong, Peoples R China
[3] Shantou Univ, Canc Hosp, Med Coll, Breast Ctr, Shantou, Guangdong, Peoples R China
[4] Guangdong Prov Key Lab Breast Canc Diag & Treatmen, Shantou, Guangdong, Peoples R China
[5] Guangdong Prov Key Lab Breast Canc Diag & Treatmen, Shantou 515041, Guangdong, Peoples R China
[6] Guangdong Procapzoom Biosci, Dept Stem Cell Res, 11 Guangpuzhong Rd, Guangzhou 510700, Guangdong, Peoples R China
关键词
CAR-NK; iPSCs; TNBC; pre-clinical; MSLN;
D O I
10.1097/CJI.0000000000000483
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The emergence of immunotherapy has introduced a promising, novel approach to cancer treatment. While multiple chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable clinical efficacy against leukemia, their effect on solid tumors has been limited. One potential option for treating solid tumors is the engineering of natural killer (NK) cells with CARs. Mesothelin (MSLN), a tumor differentiation antigen, is expressed on triple-negative breast cancer (TNBC) cells, making it a potential target for CAR-NK therapy in the treatment of TNBC. We first constructed induced pluripotent stem cells with stable anti-MSLN-CAR expression and subsequently differentiated these cells into mesothelin-targeted CAR-NK (MSLN-NK) cells. We then assessed the effects of MSLN-NK cells on TNBC cells both in vitro (using the MDA-MB-231 cell line), in vivo (in a CDX mouse model), and ex vivo (using patient-specific primary cells and patient-specific organoids), in which MSLN surface expression was confirmed. Our CDX study results indicated that MSLN-NK cells effectively killed MDA-MB-231 (MD231) cells in vitro, reduced tumor growth in the CDX mouse model of TNBC, and lysed patient-specific primary cells and patient-specific organoids derived from the tumor samples of TNBC patients. Our data demonstrated that MSLN-NK cells had high efficacy on killing TNBC cells in in vitro, in vivo, and ex vivo. Therefore, MSLN-NK could be a promising treatment option for TNBC patients.
引用
收藏
页码:285 / 294
页数:10
相关论文
共 50 条
  • [1] Understanding the Interplay of CAR-NK Cells and Triple-Negative Breast Cancer: Insights from Computational Modeling
    Arabameri, Abazar
    Arab, Samaneh
    BULLETIN OF MATHEMATICAL BIOLOGY, 2024, 86 (02)
  • [2] Understanding the Interplay of CAR-NK Cells and Triple-Negative Breast Cancer: Insights from Computational Modeling
    Abazar Arabameri
    Samaneh Arab
    Bulletin of Mathematical Biology, 2024, 86
  • [3] Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer
    Saliu, Muhammad Auwal
    Wang, Qi
    Salisu, Mansur Dabai
    Ren, Yuanfeng
    Zhang, Pengchao
    Suleiman, Rabiatu Bako
    Cao, Bingbing
    Xu, Yiqiao
    Liu, Xudong
    Lluis, Frederic
    Liu, Maoxuan
    Wan, Xiaochun
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2025, 14 (01)
  • [4] Tissue factor-targeting CAR-NK cells for immunotherapy of triple-negative breast cancer.
    Hu, Zhiwei
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (04) : 106 - 106
  • [5] Targeted immunotherapy of triple-negative breast cancer by aptamer-engineered NK cells
    Chen, Zhenghu
    Zeng, Zihua
    Wan, Quanyuan
    Liu, Xiaohui
    Qi, Jianjun
    Zu, Youli
    BIOMATERIALS, 2022, 280
  • [6] Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma
    Lin, Xiaolan
    Guan, Tian
    Xu, Yien
    Li, Yun
    Lin, Yanchun
    Chen, Shaobin
    Chen, Yuping
    Wei, Xiaolong
    Li, Dongsheng
    Cui, Yukun
    Lin, Yan
    Sun, Pingnan
    Guo, Jianmin
    Li, Congzhu
    Gu, Jiang
    Yang, Wei
    Zeng, Haoyu
    Ma, Changchun
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [7] 3D Bioprinted Tumor-Stroma Models of Triple-Negative Breast Cancer Stem Cells for Preclinical Targeted Therapy Evaluation
    Gonzalez-Callejo, Patricia
    Garcia-Astrain, Clara
    Herrero-Ruiz, Ada
    Henriksen-Lacey, Malou
    Seras-Franzoso, Joaquin
    Abasolo, Ibane
    Liz-Marzan, Luis M.
    ACS APPLIED MATERIALS & INTERFACES, 2024, 16 (21) : 27151 - 27163
  • [8] Enhanced killing of triple-negative breast cancer cells by blocking LLT1-CD161 inhibitory signal to NK cells
    Marrufo, Armando Magallanes
    Mathew, Stephen O.
    Chaudhary, Pankaj
    Mathew, Porunelloor Abraham
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [9] Lysophosphatidic acid-induced proliferation of cancer stem cells in triple-negative breast cancer
    Hirata, Naoya
    Sekino, Yuko
    Kanda, Yasunari
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2016, 130 (03) : S183 - S183
  • [10] Biomimetic nanovesicles made from iPS cell-derived mesenchymal stem cells for targeted therapy of triple-negative breast cancer
    Zhao, Qingguo
    Hai, Bo
    Zhang, Xiao
    Xu, Jing
    Koehler, Brian
    Liu, Fei
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2020, 24